Education
About Us
Working with TipRanks
Follow Us
Tyra Bioscience (TYRA)
NASDAQ:TYRA
Total Valuation
Tyra Bioscience has a market cap or net worth of $483.92M. The enterprise value is ―.
Market Cap$483.92M
Enterprise Value―
Share Statistics
Tyra Bioscience has 53,177,990 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53,177,990
Owned by Insiders47.47%
Owned by Institutions7.84%
Financial Efficiency
Tyra Bioscience’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -29.82%.
Return on Equity (ROE)-0.25
Return on Assets (ROA)-0.24
Return on Invested Capital (ROIC)-29.82%
Return on Capital Employed (ROCE)-0.30
Revenue Per Employee0.00
Profits Per Employee-1.44M
Employee Count60
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tyra Bioscience is -9.20. Tyra Bioscience’s PEG ratio is -0.19.
PE Ratio-9.20
PS Ratio0.00
PB Ratio1.61
Price to Fair Value2.32
Price to FCF-7.04
Price to Operating Cash Flow-7.92
PEG Ratio-0.19
Income Statement
In the last 12 months, Tyra Bioscience had revenue of 0.00 and earned -86.48M in profits. Earnings per share was -1.51.
Revenue0.00
Gross Profit0.00
Operating Income-104.18M
Pretax Income-86.48M
Net Income-86.48M
EBITDA-104.18M
Earnings Per Share (EPS)-1.51
Cash Flow
In the last 12 months, operating cash flow was -69.77M and capital expenditures -664.00K, giving a free cash flow of -70.44M billion.
Operating Cash Flow-69.77M
Free Cash Flow-70.44M
Free Cash Flow per Share-1.32
Dividends & Yields
Tyra Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.95
52-Week Price Change-47.34%
50-Day Moving Average9.82
200-Day Moving Average14.28
Relative Strength Index (RSI)41.47
Average Volume (3m)361.30K
Important Dates
Tyra Bioscience upcoming earnings date is Aug 7, 2025, After Close (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Tyra Bioscience as a current ratio of 23.81, with Debt / Equity ratio of 1.81%
Current Ratio23.81
Quick Ratio23.81
Debt to Market Cap<0.01
Net Debt to EBITDA0.82
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tyra Bioscience has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Tyra Bioscience EV to EBITDA ratio is -6.81, with an EV/FCF ratio of -10.07.
EV to Sales0.00
EV to EBITDA-6.81
EV to Free Cash Flow-10.07
EV to Operating Cash Flow-10.17
Balance Sheet
Tyra Bioscience has $341.44M in cash and marketable securities with $6.22M in debt, giving a net cash position of -$335.22M billion.
Cash & Marketable Securities$341.44M
Total Debt$6.22M
Net Cash-$335.22M
Net Cash Per Share-$6.30
Tangible Book Value Per Share$6.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tyra Bioscience is $30.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$30.20
Price Target Upside231.87% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast6.72%